Incannex Healthcare Limited (ASX: IHL), an ASX-Listed pharmaceutical development company, today announced its partnership agreement with the University of Western Australia Centre to expand the number of clinical sites for its ongoing dose-finding trial, which is investigating the effect of drug candidate IHL-42X in adults diagnosed with Obstructive Sleep Apnoea (‘OSA’).
临床药物开发公司Incannex Healthcare Limited（ASX：IHL）今天宣布，与西澳大学睡眠科学中心合作，以扩大其正在进行的IHL-42X剂量确定试验的临床站点。IHL-42X是旨在治疗成年人阻塞性睡眠呼吸暂停（OSA）的候选药物。
临床阶段药物开发公司Incannex Healthcare (ASX：IHL)今天发布了截至2021年3月31日的三个月的季度活动报告，详细介绍了其针对广泛性焦虑症、阻塞性睡眠呼吸暂停、颅脑外伤以及三种炎性疾病的多种专有药物开发计划，以及在美国双重上市的进展。
Incannex (ASX: IHL) has decided to target 3 major markets with its drug called IHL-675A following pre-IND with the US Food and Drug Administration and confirmed its eligibility for a less costly and faster FDA registration pathway.
药物开发公司Incannex Healthcare Limited（ASX：IHL）宣布其领先候选药物IHL-675A的FDA药物适应症申请范围和注册途径所取得的巨大进展。药物将针对肺部炎症、炎症性肠病和类风湿性关节炎提交三项针对IHL-675A的新药申请，释放多用途潜能。
临床阶段药物开发公司Incannex Healthcare Limited（ASX：IHL）已获得与美国食品和药物管理局（FDA）进行PRE-IND会议的资格，会议围绕其候选药IHL-675A在急性呼吸窘迫综合征（ARDS）和败血症相关急性呼吸窘迫综合征（SAARDS）中的预防效果。
Incannex Healthcare Limited (ASX: IHL) has been granted a Pre-IND meeting with the US Food and Drug Administration that centers around IHL-675A and its proposed use in preventing Acute Respiratory Distress Syndrome (ARDS) and Sepsis Associated Acute Respiratory Distress Syndrome (SAARDS).
临床阶段药物开发公司Incannex Healthcare Limited （ASX：IHL）宣布开展第六项研究项目后已恢复交易。临床数据表明IHL的候选药物之一IHL-675A在治疗类风湿关节炎方面比现有药物Plaquenil具有更强的抗炎特效。
Incannex Healthcare Limited (ASX: IHL), a clinical-stage pharmaceutical development company, has resumed trading following the announcement of its sixth research program as more positive pre-clinical study data showed that IHL-675A, one of IHL’s drug candidates, has stronger anti-inflammatory properties in the treatment of rheumatoid arthritis than an existing medication called Plaquenil.
临床大麻药物开发公司Incannex Healthcare Limited（ASX：IHL）今日发布公告暂停交易，并称在收到第五项研究计划（关于IHL-675迷幻药）的积极结果后，即将开启第六项研究计划。IHL昨日公告和Monash大学合作研究脑外伤的进一步治疗方案。